Please assess the completion status of the following clinical trial:

Trial Title: Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria (Part 1, Run-In Period):~* Subjects must be adults with a history of moderate to severe rheumatoid arthritis;~* Subjects must be in very good rheumatoid arthritis disease control for ≥ 6 months and be in remission as defined by a Simplified Disease Activity Index ≤ 3.3 at screening and at the end of the run-in period.~* Subjects must be on etanercept 50 mg per week plus methotrexate therapy for ≥ 6 months prior to the start of the run-in period. The methotrexate dose must be 10 to 25 mg per week for ≥ 6 months prior to the start of the run-in period and the dose must be stable for ≥ 8 weeks prior to the start of the run-in period.~* Subject has no known history of active tuberculosis, and has a negative test for tuberculosis during screening.~Exclusion Criteria (Part 1, Run-In Period):~* Subject has used biologic disease modifying antirheumatic drug other than etanercept OR has used an oral janus kinase inhibitor ≤ 6 months prior to run-in visit 1~* Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to run-in visit 1.~* Subject has known alcohol addiction or dependency or uses alcohol daily.~* Subject has one or more significant concurrent medical conditions per investigator judgment, including the following:~  * poorly controlled diabetes~ * chronic kidney disease stage IIIb, IV, or V~ * symptomatic heart failure (New York Heart Association class II, III, or IV)~ * myocardial infarction or unstable angina pectoris within the past 12 months prior to randomization~ * uncontrolled hypertension~ * severe chronic pulmonary disease (eg, requiring oxygen therapy)~ * multiple sclerosis or any other demyelinating disease~ * major chronic inflammatory disease or connective tissue disease other than rheumatoid arthritis (eg, systemic lupus erythematosus with the exception of secondary Sjögren's syndrome)~Inclusion Criteria (Part 2, Treatment Period):~* SDAI ≤ 3.3 at run-in visit 3~* Subject if female and not at least 2 years postmenopausal or history of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, has a negative urine pregnancy test at baseline (day 1).~Exclusion Criteria (Part 2, Treatment Period):~* Any clinically significant change in the Part 1 eligibility criteria during the run-in period~* SDAI \> 3.3 and ≤ 11 on two consecutive visits at least two weeks apart OR SDAI \> 3.3 and ≤ 11 on two or more separate visits OR SDAI \> 11 at any time during the run-in period~* Subject has a clinically significant laboratory abnormality during run-in period which in the opinion of the investigator poses a safety risk, will prevent the subject from completing the study, or will interfere with the interpretation of the study results during the run-in period.~NOTE: Other inclusion/exclusion criteria may apply per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label Run-In: Etanercept plus Methotrexate (Type: EXPERIMENTAL): Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
- Double-Blind Treatment: Methotrexate Monotherapy (Type: EXPERIMENTAL): Oral methotrexate 10 to 25 mg weekly plus placebo for etanercept for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg).
- Double-Blind Treatment: Etanercept Monotherapy (Type: EXPERIMENTAL): Etanercept 50 mg weekly by subcutaneous injection plus placebo for methotrexate for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg).
- Double-Blind Treatment: Etanercept plus Methotrexate (Type: EXPERIMENTAL): Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will continue on the assigned treatments (as rescue treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).